Envafolimab (ASC 22; KN 035) is a recombinant fusion protein comprising a humanized single-domain anti-PD-L1 antibody linked to the Fc fragment of a human IgG1 antibody. This biologic is designed to inhibit the interaction between PD-L1 and PD-1, exhibiting an IC50 value of 5.25 nM, indicative of its potent inhibitory activity. Envafolimab is primarily utilized in research focused on solid tumors, providing a valuable tool for investigating the therapeutic potential of PD-L1 blockade in oncology.
Envafolimab (ASC 22; KN 035) is a recombinant fusion protein comprising a humanized single-domain anti-PD-L1 antibody linked to the Fc fragment of a human IgG1 antibody. This biologic is designed to inhibit the interaction between PD-L1 and PD-1, exhibiting an IC50 value of 5.25 nM, indicative of its potent inhibitory activity. Envafolimab is primarily utilized in research focused on solid tumors, providing a valuable tool for investigating the therapeutic potential of PD-L1 blockade in oncology.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
